Citigroup
TVTX icon

Citigroup’s Travere Therapeutics TVTX Stock Holding History

Citigroup’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-500
Closed -$7K – 7780
2019
Q4 		$7K Sell
500
-32,500
-98% -$415K ﹤0.01% 7320
2019
Q3 		$382K Buy
33,000
+800
+2% +$13.2K ﹤0.01% 4595
2019
Q2 		$647K Buy
32,200
+29,300
+1,010% +$579K ﹤0.01% 4158
2019
Q1 		$66K Buy
2,900
+100
+4% +$2.21K ﹤0.01% 6112
2018
Q4 		$63K Sell
2,800
-9,000
-76% -$224K ﹤0.01% 6046
2018
Q3 		$339K Buy
11,800
+1,800
+18% +$51.5K ﹤0.01% 4708
2018
Q2 		$273K Buy
+10,000
New +$266K ﹤0.01% 4737
2017
Q2 		– Sell
-1,500
Closed -$28K – 7485
2017
Q1 		$28K Buy
1,500
+1,200
+400% +$23.5K ﹤0.01% 6077
2016
Q4 		$6K Buy
+300
New +$6.13K ﹤0.01% 6882

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citigroup's TVTX Position: Q1 2026 in Review

Citigroup increased its Travere Therapeutics (TVTX) stake by 0.07% in Q1 2026, buying an estimated $598 and bringing the position to 27,131 shares worth $806K. The position accounts for ﹤0.01% of the portfolio, ranked #3248.

Citigroup first reported a position in TVTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $8.14M in Q1 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Citigroup held 27,131 shares of Travere Therapeutics worth $806K as of Q1 2026.
  • Citigroup bought 20 Travere Therapeutics shares in Q1 2026, an estimated $598.
  • Travere Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3248 holding.
  • Citigroup first reported a position in Travere Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Citigroup's Travere Therapeutics position peaked at $8.14M in Q1 2023.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.